Sign in
Taking people in United KingdomNo phase

Blood test for tumour DNA when cancer grows despite treatment

Tests a tumour DNA blood test in people whose cancer grew.

Key facts

Who runs it
Royal Marsden NHS Foundation Trust
Where
London, United KingdomSee the site
Trial code
Registry title
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
Status
Recruiting
People taking part
100 people, planned
Started
23 May 2025
Expected to end
31 Dec 2026
Type of study
Interventional
Treatments tested
  • Marsden360 ctDNA test and GTAB review
Record updated
29 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced or metastatic lung, GIST, colorectal, biliary tract or ovarian cancer whose cancer has grown during treatment. They are treated at The Royal Marsden and have a blood test to check the cancer's DNA.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Metastatic or unresectable disease. Five cancer groups: non-small cell lung cancer with a known driver gene change, GIST, left-sided RAS wild type colorectal cancer, biliary tract cancer with a targetable change, and high-grade ovarian cancer.
Earlier treatment
The cancer must have grown on treatment within the 6 weeks before consent: targeted therapy (lung, GIST, biliary tract), an anti-EGFR drug such as cetuximab (colorectal; first-line treatment if HER2 positive), or a PARP inhibitor after platinum-based therapy (ovarian).
Biomarker or test result
Lung: a known driver gene change such as EGFR, ALK, ROS1, RET, MET, BRAF, NTRK, HER2 or KRAS. Colorectal: RAS wild type. Biliary tract: IDH1 mutation, HER2 amplification, FGFR2 fusion or rearrangement, NTRK fusion, BRAF V600E mutation or dMMR. Ovarian: known BRCA status.

Main reasons for not taking part

  • Too unwell to give the blood samples the study needs
  • ECOG performance status of 3 or higher
  • Not being treated by the medical oncology service at Royal Marsden Hospital

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • All cohorts:
  • Age ≥18 years old
  • Ability to provide written informed consent
  • Presence of metastatic or unresectable disease
  • Being reviewed and treated through medical oncology service at Royal Marsden Hospital; Cohort 1: Locally Advanced/Metastatic NSCLC
  • Oncogene-addicted NSCLC (i.e. ESCAT Tier 1 oncogenic drivers: EGFR/ALK/ROS1/RET/MET/BRAF/NTRK/HER2/KRAS), AND
  • Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent; Cohort 2: Locally Advanced/Metastatic GIST
  • Locally advanced/metastatic gastrointestinal stromal tumour (GIST), AND
  • Progressive disease on targeted therapy (any line) within the 6 weeks prior to consent; Cohort 3: Metastatic Colorectal Cancer
  • Metastatic colorectal cancer, left sided, RAS wild type, HER2 any status, AND
  • If HER2 negative or unknown: progressive disease on systemic anti-cancer therapy (SACT) with an anti-EGFR agent (e.g. cetuximab) within the 6 weeks prior to consent
  • If HER2 positive: progressive disease on first line systemic anti-cancer therapy (SACT) +/- an anti-EGFR agent within the 6 weeks prior to consent; Cohort 4: Locally Advanced/Metastatic BTC
  • Identified targetable mutation (IDH1 mutation/HER2 amplification/FGFR2 fusion or rearrangement/NTRK fusion/BRAF V600E mutation/MMR deficiency [dMMR]), AND
  • Progressive disease on targeted therapy (any line) demonstrated within the 6 weeks prior to consent; Cohort 5: Advanced/Metastatic ovarian cancer
  • Diagnosis of advanced/metastatic high-grade ovarian cancer, AND
  • Known BRCA status, AND
  • Progressive disease on a PARP-inhibitor (with or without bevacizumab) following platinum-based therapy in the 1st line maintenance setting, within the 6 weeks prior to consent

Who cannot take part

  • All cohorts:
  • Medically unstable to commit to sampling required for the study
  • ECOG performance status ≥3

Where in United Kingdom

  • Royal Marsden NHS Foundation TrustLondon, United KingdomContact: Rebecca BrooksTaking people

About the trial

What the trial wants to find out

ctDNA stands for circulating tumour DNA. As ctDNA is released by tumour cells into the blood stream, taking a blood sample and analysing it for ctDNA, can provide a lot of useful information about a patient's cancer. In certain situations, ctDNA can be used to screen for or detect cancer early, to aid clinical decisions about which treatment to give a patient, to provide information about if a cancer has become resistant to treatment, or provide information about how much cancer may be left after treatment (residual disease).

Read full original descriptionShow less

The aim of this trial is to establish the clinical utility of implementing ctDNA testing in cancer patients with a view to enhance the delivery of personalised care within the National Health Service in the United Kingdom (UK).

One hundred patients will be recruited, with 20 from each of the following cancer types:

* Non-small cell lung cancer * Gastrointestinal stromal tumours * Colorectal cancer * Biliary tract cancer * Ovarian cancer.

Patients must be aged 18 or over, must have had progressive disease whilst receiving anti-cancer treatment, and must be being treated at The Royal Marsden.

Patients will have a blood sample taken and analysed using the Marsden360 ctDNA test. The results of the test will be looked at by The Royal Marsden Genomic Tissue Advisory Board (GTAB), and for each individual patient, the GTAB will determine if having a ctDNA test helped to personalise their care by:

* Aiding the identification of a genomically-matched standard of care therapy * Aiding the identification of a genomically-matched clinical trial (based in the UK) * Offering additional prognostic information not otherwise available through standard of care testing * Negating the need for a tissue biopsy.

The group in the trial

  • Patients who have had progressive disease on therapy within the 6 weeks prior to consentOther group

    Treatment: Marsden360 ctDNA test and GTAB review

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine: A Tumour Agnostic Study
Plain-language title
Blood test for tumour DNA when cancer grows despite treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 June 2026